Fluconazole Treatment Is Effective against a Candida albicans erg3/erg3 Mutant In Vivo Despite In Vitro Resistance
Open Access
- 1 February 2006
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 50 (2), 580-586
- https://doi.org/10.1128/aac.50.2.580-586.2006
Abstract
Candida albicans ERG3 encodes a sterol C5,6-desaturase which is essential for synthesis of ergosterol. Defective sterol C5,6 desaturation has been considered to be one of the azole resistance mechanisms in this species. However, the clinical relevance of this resistance mechanism is still unclear. In this study, we created a C. albicans erg3/erg3 mutant by the “Ura-blaster” method and confirmed the expected azole resistance using standard in vitro testing and the presence of ergosta-7,22-dien-3β-ol instead of ergosterol. For in vivo studies, a wild-type URA3 was placed back into its native locus in the erg3 homozygote to avoid positional effects on URA3 expression. Defective hyphal formation of the erg3 homozygote was observed not only in vitro but in kidney tissues. A marked attenuation of virulence was shown by the longer survival and the lower kidney burdens of mice inoculated with the reconstituted Ura + erg3 homozygote relative to the control. To assess fluconazole efficacy in a murine model of disseminated candidiasis, inoculum sizes of the control and the erg3 homozygote were chosen which provided a similar organ burden. Under these conditions, fluconazole was highly effective in reducing the organ burden in both groups. This study demonstrates that an ERG3 mutation causing inactivation of sterol C5,6-desaturase cannot confer fluconazole resistance in vivo by itself regardless of resistance measured by standard in vitro testing. The finding questions the clinical significance of this resistance mechanism.Keywords
This publication has 35 references indexed in Scilit:
- Evolution of antifungal-drug resistance: mechanisms and pathogen fitnessNature Reviews Microbiology, 2005
- Temporal events in the intravenous challenge model for experimental Candida albicans infections in female miceMycoses, 2005
- Ectopic Expression of URA3 Can Influence the Virulence Phenotypes and Proteome of Candida albicans but Can Be Overcome by Targeted Reintegration of URA3 at the RPS10 LocusEukaryotic Cell, 2004
- Nitrogen metabolism and virulence of Candida albicans require the GATA‐type transcriptional activator encoded by GAT1Molecular Microbiology, 2003
- Evaluation of the Roles of Four Candida albicans Genes in Virulence by Using Gene Disruption Strains That Express URA3 from the Native LocusInfection and Immunity, 2003
- Candida albicans Mutations in the Ergosterol Biosynthetic Pathway and Resistance to Several Antifungal AgentsAntimicrobial Agents and Chemotherapy, 2003
- Resistance Mechanisms in Clinical Isolates of Candida albicansAntimicrobial Agents and Chemotherapy, 2002
- Emergence of azole drug resistance in Candida species from HIV-infected patients receivingprolonged fluconazole therapy for oral candidosisJournal of Antimicrobial Chemotherapy, 1995
- Molecular mechanisms of drug resistance in fungiTrends in Microbiology, 1994
- Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patientsAIDS, 1994